Rexahn's Akt inhibitor increases pancreatic cancer survival time 50%
This article was originally published in Scrip
Executive Summary
Rexahn Pharmaceuticals potential first-in-class inhibitor of the Akt protein kinase in cancer cells, Archexin, provided metastatic pancreatic cancer with a survival rate that was more than 50% higher than historical rates for the standard of care. The data came from a 31-patient Phase IIa clinical trial. The Rockville, Maryland company will have to conduct a Phase IIb study in a larger pool of hard-to-treat patients to try to replicate the survival benefit.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.